Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab plus ISA101b in recurrent/metastatic HPV16-positive oropharyngeal cancer after prior anti-PD-1 progression
2020-003652-32Phase 2Terminated
- Sponsor
- ISA Pharmaceuticals
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and SLP-HPV-01 in oropharyngeal cancer, sponsored by ISA Pharmaceuticals. Primary endpoint: Objective response rate. Started Dec 2020; status: terminated.
02
Drugs
cemiplimabSLP-HPV-01
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on 2020-003652-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003652-32.